precision pharmacy tirzepatide New Pricing, Access to Available Through Self-Pay Options Tirzepatide Injection - The Pharmacy

Start My Program From $299/mo Medication + visits + support We come to you A member of our team will contact you within one business day

Both Wegovy and Saxenda are approved for the treatment of obesity

However, CMS announced the Medicare GLP-1 Bridge demonstration in December 2025, which will allow Medicare beneficiaries to access GLP-1 obesity medications starting July 2026 , with a longer-term BALANCE Model launching in Medicare Part D by January 2027 ( [18] )

This transparent pricing applies across all three commitment tiers

doi: 10.3389/fmed.2026.1764664 Received 10 December 2025 Revised 25 March 2026 Accepted 30 March 2026 Published 22 April 2026 Volume 13 - 2026 Edited by Isabella Panfoli, University of Genoa, Italy Reviewed by Raffaele Carraro, La Princesa University Hospital, Spain Kumar Ashish, CarolinaEast Medical Center, United States Updates Copyright 2026 Harbi, Ashour, Alorfi, Aldurdunji, Wali and Alzahrani